Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/03/2022* -- Results Q3 2022 -- 4.54 --
11/03/2022* 09:00 EST Earnings Call Q3 2022 -- -- --
08/03/2022 -- Results Q2 2022 3.46 4.54 -23.82%
08/03/2022 09:00 EST Earnings Call Q2 2022 -- -- --
05/04/2022 -- Results Q1 2022 4.71 3.65 29.23%
05/04/2022 09:00 EST Earnings Call Q1 2022 -- -- --
02/24/2022 -- Results Q4 2021 3.51 4.05 -13.29%
02/24/2022 09:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/03/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/03/2022
Beat/Miss Upgrade
Return Since -7.21%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
URL https://www.unither.com
Investor Relations URL https://ir.unither.com/
HQ State/Province Maryland
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Blend
Next Earnings Release Nov. 03, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
20.94%
-8.42%
3.15%
-26.39%
-19.12%
72.33%
42.35%
-1.86%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-19.66%
--
--
--
--
-80.26%
-30.99%
65.08%
14.58%
-72.20%
-56.09%
-27.12%
-54.31%
21.70%
142.6%
39.62%
-27.92%
-47.88%
-66.86%
-34.25%
-72.63%
115.4%
103.8%
-22.98%
137.9%
--
--
--
--
94.97%
-27.56%
-20.42%
-69.00%
As of October 05, 2022.

Profile

Edit
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
URL https://www.unither.com
Investor Relations URL https://ir.unither.com/
HQ State/Province Maryland
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Blend
Next Earnings Release Nov. 03, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
FBT 38.96M USD 2.97%
FTHAX 122.28M USD 2.17%
DLRHX 18.49M USD 2.11%
HBMCX 23.97M USD 1.82%
HFMRX 149.78M USD 1.82%
FBIOX 86.58M USD 1.72%
FDMLX 123.07M USD 1.57%
XBI 72.13M USD 1.03%
IBB 70.62M USD 0.95%
IJH 277.38M USD 0.50%
MDY 88.22M USD 0.50%
SPMD 24.17M USD 0.49%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter UTHR Tweets